<?xml version='1.0' encoding='utf-8'?>
<document id="21597286"><sentence text="Suspicion of drug-drug interaction between high-dose methotrexate and proton pump inhibitors: a case report - should the practice be changed?"><entity charOffset="53-65" id="DDI-PubMed.21597286.s1.e0" text="methotrexate" /></sentence><sentence text="We report a case of a potential drug-drug interaction in a woman treated by a first injection of high-dose methotrexate for a T-lymphoblastic lymphoma"><entity charOffset="107-119" id="DDI-PubMed.21597286.s2.e0" text="methotrexate" /></sentence><sentence text=" Valaciclovir, fluoxetine and pantoprazole were given concomitantly"><entity charOffset="1-13" id="DDI-PubMed.21597286.s3.e0" text="Valaciclovir" /><entity charOffset="15-25" id="DDI-PubMed.21597286.s3.e1" text="fluoxetine" /><entity charOffset="30-42" id="DDI-PubMed.21597286.s3.e2" text="pantoprazole" /><pair ddi="false" e1="DDI-PubMed.21597286.s3.e0" e2="DDI-PubMed.21597286.s3.e0" /><pair ddi="false" e1="DDI-PubMed.21597286.s3.e0" e2="DDI-PubMed.21597286.s3.e1" /><pair ddi="false" e1="DDI-PubMed.21597286.s3.e0" e2="DDI-PubMed.21597286.s3.e2" /><pair ddi="false" e1="DDI-PubMed.21597286.s3.e1" e2="DDI-PubMed.21597286.s3.e1" /><pair ddi="false" e1="DDI-PubMed.21597286.s3.e1" e2="DDI-PubMed.21597286.s3.e2" /></sentence><sentence text=" A methotrexate overdosage was shown at 36 h after infusion associated with a severe renal failure"><entity charOffset="3-15" id="DDI-PubMed.21597286.s4.e0" text="methotrexate" /></sentence><sentence text=" Alkaline hyperhydration, folinic acid and carboxypeptidase G2 were given"><entity charOffset="26-38" id="DDI-PubMed.21597286.s5.e0" text="folinic acid" /></sentence><sentence text=" Prescription analyses by pharmacists and literature research have permitted us to suggest that a drug-drug interaction between methotrexate and proton pump inhibitors (PPI) was responsible for this renal failure"><entity charOffset="128-140" id="DDI-PubMed.21597286.s6.e0" text="methotrexate" /></sentence><sentence text=" Several mechanisms of interaction were suggested and might be related to the inhibition of renal methotrexate transporters by PPI, an increase in the methotrexate efflux to the blood by an upregulation of multidrug resistance protein 3 by PPI or genetic polymorphisms"><entity charOffset="98-110" id="DDI-PubMed.21597286.s7.e0" text="methotrexate" /><entity charOffset="151-163" id="DDI-PubMed.21597286.s7.e1" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.21597286.s7.e0" e2="DDI-PubMed.21597286.s7.e0" /><pair ddi="false" e1="DDI-PubMed.21597286.s7.e0" e2="DDI-PubMed.21597286.s7.e1" /></sentence><sentence text=" This case shows that pharmacists can help physicians to optimize patient treatment: they consensually decided on the systematic discontinuation of PPI or a switch to ranitidine when patients were treated by high-dose methotrexate"><entity charOffset="167-177" id="DDI-PubMed.21597286.s8.e0" text="ranitidine" /><entity charOffset="218-230" id="DDI-PubMed.21597286.s8.e1" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.21597286.s8.e0" e2="DDI-PubMed.21597286.s8.e0" /><pair ddi="false" e1="DDI-PubMed.21597286.s8.e0" e2="DDI-PubMed.21597286.s8.e1" /></sentence><sentence text="" /></document>